CD86 and B-cell non-Hodgkin lymphoma: In addition to known NK-activating ligands such as UL16 binding proteins (ULBP), we also determined the expression of molecules shown to play key roles in NK cell cytotoxicity, particularly in the context of B cell lymphomas, such as CD80, CD86, CD70, and CD72 (59–63).